In recent work we showed that the EGF receptor (EGFr) was activated in tumor promoter treated mouse epidermis (Cell Growth & Dierentiation, 6: 1447 ± 1455. In the present study, we have investigated the possible role of other erbB family members in the process of tumor promotion. Both erbB2 and erbB3, but not erbB4, were expressed in cultured mouse keratinocytes and in mouse epidermis in vivo. In cultured mouse keratinocytes, EGF stimulated rapid tyrosine phosphorylation of erbB2 followed by a time-dependent degradation of erbB2 protein. Furthermore, an increase in erbB2 : EGFr heterodimer formation was also induced by EGF. In contrast to the results with erbB2, EGF did not induce tyrosine phosphorylation, the degradation of erbB3, or erbB3 : EGFr heterodimer formation in cultured keratinocytes. Further analyses revealed that c-src kinase activity was dramatically elevated in cultured mouse keratinocytes exposed to EGF. In mouse epidermis following multiple treatments with 12-O-tetradecanoylphorbol-13-acetate (TPA), the phosphotyrosine content of erbB2 was signi®cantly elevated in a dose-dependent manner. Concomittantly, erbB2 : EGFr heterodimer formation and c-src kinase activity were also elevated in TPA-treated epidermis. Structure-activity relationships with several phorbol ester analogs showed that the elevated phosphorylation of erbB2 in mouse epidermis followed closely with tumor promoting ability. Activation of erbB2 and c-src kinase were also observed in the epidermis of TGFa transgenic mice where expression of human TGFa was targeted to basal keratinocytes with the human K14 promoter. Collectively, the current data suggest that the activation of erbB2 in phorbol ester treated skin can be explained solely by a mechanism involving elevation of EGFr ligands and activation of the EGFr. In addition, activation of c-src may be an important downstream eector in mouse keratinocytes both in vivo and in vitro, following activation of the EGFr, erbB2, or both.
Introduction
The tumor promotion stage of multistage mouse skin carcinogenesis is characterized by the induction of hyperplasia accompanied by sustained epidermal cell proliferation (DiGiovanni, 1992) . Repeated tumor promoter treatment eventually leads to the outgrowth of premalignant papillomas, some of which will progress to squamous cell carcinomas (SCCs) (Slaga, 1983 (Slaga, , 1989 DiGiovanni, 1992) . It is generally accepted that all skin tumor promoting agents ultimately lead to the selective clonal expansion of initiated cells although the exact biochemical and molecular mechanisms may dier among promoting stimuli (Parkinson, 1985; Blumberg, 1988; Slaga, 1989; Yuspa, 1994) . While genetic mechanisms have been postulated to play a role in the tumor promotion stage (DiGiovanni, 1992) , the eventual reversibility of promoter-induced eects (Aldaz et al., 1985; Ewing et al., 1988a) argues that this stage is accomplished primarily through epigenetic mechanisms as originally postulated by Boutwell and others (Raick et al., 1972; Boutwell, 1976; DiGiovanni, 1992) .
Receptor tyrosine kinases (RTKs) are involved in growth control and alterations in several of these ligand/receptor systems may result in uncontrolled growth and oncogenic transformation (Ullrich and Schlessinger, 1990; Aaronson, 1991) . One of the best studied RTK families is the type 1 growth factor receptors, also called the erbB family. The epidermal growth factor receptor (EGFr or erbB1) was the ®rst member to be cloned and showed considerable homology to the avian erythroblastosis virus transforming protein, v-erbB (Ullrich et al., 1984) . ErbB2 is the human homologue of the neu oncogene which was initially isolated from chemically induced rat neuroblastomas (Shih et al., 1979 (Shih et al., , 1981 and shares close homology with the EGFr (Bargmann et al., 1986) . The erbB family also includes two recently identi®ed members, erbB3 (Kraus et al., 1989; Plowman et al., 1990) and erbB4 (Plowman et al., 1993) . All erbB family members share a similar primary structure with a ligand binding extracellular domain, a transmembrane domain, and an intracellular domain which contains a highly conserved tyrosine kinase domain and a carboxyl terminus (Ullrich and Schlessinger, 1990: Mason and Gullick, 1995) . The binding of EGF to its cognate receptor leads to activation of the intrinsic tyrosine kinase and phosphorylation on multiple tyrosine residues on its carboxyl terminus. The mechanism of phosphorylation on carboxyl terminal tyrosine residues is believed to occur through receptor dimerization (homo-and/or heterodimerization) and transphosphorylation (Lemmon and Schlessinger, 1994) . The phosphotyrosines then serve as recognition sites for src homology-2 (SH2) containing proteins, which in turn trigger cascades of events that propagate the signal from the membrane to the nucleus (Pawson and Schlessinger, 1993) .
Although all erbB family members share a similar primary structure, receptor activation mechanism, and signal transduction pattern, as described above, they bind to dierent ligands. EGFr binds to EGF, TGFa (MassagueÂ , 1990) , amphiregulin (Shoyab et al., 1989) , Heparin-binding EGF-like growth factor (Marikovsky et al., 1993) , and Betacellulin (Shing et al., 1993) . erbB3 and erbB4 bind to Neu dierentiation factor (NDF) or heregulin which has at least ten isoforms (Holmes et al., 1992; Ben-Baruch and Yarden, 1994) . However, a speci®c ligand for erbB2 has not been identi®ed at the present time .
Alterations in erbB2 signaling have been implicated in neoplastic transformation in vitro and in human cancer. Overexpression of erbB2 occurs in 20 ± 30% of breast and ovarian cancers and correlates with poor prognosis in both types of cancer (Slamon et al., 1987 (Slamon et al., , 1989 . The transforming or oncogenic activity of neu has been demonstrated in cell lines transfected with the proto-oncogene or in transgenic mice overexpressing the neu oncogene. For example, overexpression of the normal coding sequence of the rat neu gene using LTR-based expression vectors in NIH3T3 cells caused cell transformation (Di Marco et al., 1990) . In addition, overexpression of neu under control of the mouse mammary tumor virus (MMTV) promoter in transgenic mice resulted in the appearance of focal mammary tumors after long latency (Guy et al., 1992) . Expression of the neu oncogene under control of the MMTV promoter in transgenic mice resulted in multifocal mammary adenocarcinomas that involved the entire epithelium and both mammary glands (Muller et al., 1988; Guy et al., 1996) . It was suggested that an appropriate level of activated neu is sucient for rapid production of mammary tumors in transgenic mice (Guy et al., 1996) .
The mechanism for transformation by overexpression of erbB2/neu is unclear, due, in part, to the lack of speci®c ligand(s) for this RTK. However, erbB2 has been found to form heterodimers with the EGFr and the NDF receptors (erbB3 and erbB4), which suggests a mechanism for erbB2 activation without the involvement of a direct erbB2 ligand (SpivakKroizman et al., 1992; Carraway and Cantley, 1994; Karunagaran et al., 1996) . We recently demonstrated that the EGFr becomes activated in mouse epidermis following topical treatment with diverse tumor promoters (Xian et al., 1995) . In the present study, we have examined whether erbB2 also plays a role in skin tumor promotion. For this purpose, we examined whether the tyrosine phosphorylation state of erbB2 was altered and whether erbB2 and EGFr formed heterodimers in cultured mouse keratinocytes exposed to EGF and in tumor promoter-treated mouse epidermis. In addition, we examined whether c-src, a recently identi®ed downstream signaling component of erbB2 activation (Muthuswamy et al., 1994) , becomes activated in EGF-stimulated keratinocytes and in tumor promoter-treated mouse epidermis. The data demonstrate that both erbB2 and c-src are activated in cultured mouse keratinocytes exposed to EGF and in TPA-treated mouse epidermis in vivo, and suggest a possible role for these changes in the tumor promotion stage of multistage skin carcinogenesis.
Results

Dose-dependence and time course of tyrosine phosphorylation induced by EGF in cultured mouse keratinocytes
Initial experiments examined the dose-dependence of protein tyrosine phosphorylation induced by EGF in cultured keratinocytes from adult SENCAR mice. Mouse epidermal basal cells were isolated and cultured in low Ca 2+ MEM-2 medium with 1% FBS and supplements. Cells were starved for 24 h at day 3, stimulated with 0.1 ± 100 ng/ml of EGF for 1 min, and cell lysates were prepared as described in Materials and methods. Cell lysates were subjected to Western blot analysis using anti-phosphotyrosine antibody. As shown in Figure 1a , EGF (concentrations51 ng/ml) stimulation led to an increase in phosphotyrosine content in protein bands of M r 175 ± 190 kD, 135 kD, 125 kD, and 58 kD. Protein phosphorylation reached a maximum at a concentration of 40 ng/ml EGF. Thus, the 40 ng/ml concentration was used throughout the rest of the experiments. The time course of protein tyrosine phosphorylation induced by EGF in cultured keratinocytes was also examined as shown in Figure  1b . Cells were stimulated with 40 ng/ml of EGF for 0.5 ± 30 min, lysed, and then cell lysates were subjected to Western blot analysis using the anti-phosphotyrosine antibody. Phosphotyrosine levels of all protein bands reached a peak within 1 min after exposure to EGF, and then started diminishing after about 3 min and had nearly returned to basal levels by 30 min.
The major tyrosine phosphorylation band at M r 175 ± 190 kD was in fact composed of two bands of 175 kD and 190 kD (seen more readily when the ®lm was exposed for a shorter period of time (data not shown). To tentatively identify these two major tyrosine phosphorylation bands, the same samples were subjected to Western blot analysis using speci®c antibodies against dierent members of the erbB family. As shown in Figure 1b , the EGFr co-migrated with the 175 kD band, while erbB2 and erbB3 co-migrated with the 190 kD band. Interestingly, erbB4 could not be detected in primary mouse keratinocytes under our current experimental conditions (data not shown).
EGF-induced tyrosine phosphorylation and degradation of EGFr and erbB2 in cultured mouse keratinocytes
In light of the data shown in Figure 1 , we further examined the time courses for tyrosine phosphorylation of individual erbB family members induced by EGF in cultured keratinocytes. For these experiments, each member of the erbB family detected in cultured keratinocytes was immunoprecipitated using speci®c antibodies and then the protein levels and phosphotyrosine levels were analysed in Western blot analyses. As shown in Figure 2a , the phosphotyrosine levels of the EGFr and erbB2 increased dramatically 30 s after exposure to EGF with a time course similar to that shown in Figure 1b for the protein bands in the 175 ± 190 kD range. However, the phosphotyrosine level of erbB3 was unaected by EGF stimulation and remained low and relatively constant throughout the experimental period. Analysis of the relative levels of the EGFr and erbB2 proteins showed that each erbB2 and c-src activation in mouse keratinocytes W Xian et al decreased in a time-dependent manner upon EGF stimulation of cells. In contrast, the level of erbB3 protein remained essentially unchanged over the time course examined. Quantitation of the protein levels of dierent erbB family members following immunoprecipitation is shown in Figure 2b . Using the immunoprecipitation method, erbB4 still could not be detected in Western blot analysis (data not shown). The time dependent loss of EGFr and erbB2 (but not erbB3) protein was also con®rmed in direct Western blot experiments using whole cell lysates (data not shown).
erbB2 : EGFr heterodimer formation in cultured mouse keratinocytes exposed to EGF
Since EGF is not a ligand for erbB2, the rapid increase in phosphotyrosine level in erbB2 after exposure to EGF could result from heterodimer formation and transphosphorylation between EGFr and erbB2 . To test this hypothesis, cultured keratinocytes were stimulated with EGF for 1 min and cell lysates were prepared as described in Materials and methods. Cell lysates (1 mg of protein) were immunoprecipitated with anti-EGFr antibody and subjected to Western blot analysis using both antiEGFr and anti-erbB2 antibody. A representative experiment is shown in Figure 3a . As shown, a reduced amount of EGFr was immunoprecipitated from lysates from EGF-stimulated cells relative to the lysates from control cells, which was consistent with the data summarized in Figure 2 . However, an almost identical amount of erbB2 was co-immunoprecipitated with the EGFr from both EGF-stimulated and control cells. When normalized against the EGFr protein level, more erbB2 protein (*threefold) was co-immunoprecipitated from EGF-stimulated cells than from the control cells ( Figure 3b ). In contrast, no evidence for erbB3 : EGFr heterodimer formation was obtained (data not shown).
Elevated erbB2 phosphorylation and erbB2 : EGFr heterodimer formation following treatment of mouse epidermis with TPA
We have recently demonstrated that the EGFr becomes activated in mouse epidermis in vivo following treatment with diverse skin tumor promoters and also showed that the EGFr was activated in skin tumors from SENCAR mice (Xian et al., 1995) . Since erbB2 exhibited elevated phosphotyrosine content and formed more heterodimer with EGFr after stimulation of cultured mouse keratinocytes with EGF (Figures 2 and 3, respectively), we further examined the phosphotyrosine level of erbB2 in TPA-treated mouse epidermis in vivo. Mice were treated topically with three applications of acetone or 3.4 nmol TPA and sacri®ced 3 h, 6 h, and 24 h after the last treatment.
Epidermal lysates were immunoprecipitated with antia b Figure 1 Dose-dependence and time course of protein tyrosine phosphorylation induced by EGF in primary cultures of mouse keratinocytes. Mouse epidermal basal cells were isolated and cultured in low Ca 2+ MEM-2 medium with 1% FBS and supplements. Cells were starved for 24 h at day 3 prior to EGF stimulation and then lysed in lysis buer at various times thereafter. (a) Dose dependence of protein tyrosine phosphorylation after stimulation with 0.1 ± 100 ng/ml of EGF for 1 min. Cell lysates were subjected to Western blot analysis using antiphosphotyrosine antibody (PY20). (b) Time course of protein tyrosine phosphorylation after stimulated with 40 ng/ml of EGF for 0.5 ± 30 min. Cell lysates were subjected to Western blot analysis using PY20 (left panel). Cell lysates (harvested after stimulation with EGF for 30 s) were subjected to Western blot analysis using antibodies speci®c to individual erbB proteins (right panel). The molecular weight markers are in kDa or kD a b
Figure 2 EGF-induced tyrosine phosphorylation and degradation of EGFr and erbB2 in cultured mouse keratinocytes. Cultured keratinocytes were stimulated with 40 ng/ml EGF for 0.5 ± 30 min and lysed in lysis buer. (a) Cell lysates (500 mg of protein) were immunoprecipitated with 5 mg of polyclonal antiEGFr, anti-erbB2, or anti-erbB3 antibody, respectively, and subjected to Western blot analysis using corresponding antibody or PY20. The PY20 blots for EGFr and erbB3 were exposed for twice the amount of time compared to that for erbB2. (b) Relative receptor protein levels (mean+SE, n=4) in (a) erbB2 antibody and subjected to Western blot analysis. As shown in Figure 4a , similar levels of erbB2 protein were immunoprecipitated from epidermal tissue preparations using either control or TPA-treated mice. However, the phosphotyrosine level of erbB2 was dramatically elevated in samples from the TPA-treated mice compared to samples from the control mice.
To further study the biological relevance for elevated erbB2 phosphotyrosine in skin tumor promotion, we investigated whether there was a correlation between the increase in erbB2 phosphotyrosine level and tumorpromoting activity. For these experiments, we examined three dierent dose levels of TPA in the linear range for tumor-promoting activity in SENCAR mice (Ewing et al., 1988b) . In addition, the eects of two phorbol ester analogs, 4a-phorbol 12,13-didecanoate (4a-PDD) and phorbol 12,13-didecanoate (PDD), were examined. As shown in Figure 4b , there was a strong correlation between the increase in erbB2 phosphotyrosine level in mouse epidermis and the increase in the dose of TPA. 4a-PDD, which has no tumor-promoting activity, had no eect on the phosphotyrosine level of erbB2 when applied at a 10 nmol dose. In contrast, PDD, which is a weak skin tumor promoter, produced a moderate increase in phosphotyrosine level of erbB2 at a 10 nmol dose, similar to that produced by TPA at a much lower dose (0.85 nmol).
Since erbB2 : EGFr heterodimer formation was detected in cultured keratinocytes ( Figure 3 ) and erbB2 phosphotyrosine level was signi®cantly elevated in TPA-treated epidermis (Figure 4) , we further examined whether heterodimer formation also occurred in vivo following TPA treatment. Mice were treated topically with three applications of acetone or 3.4 nmol TPA and sacri®ced 6 h after the last treatment. Epidermal microsomal preparations were subjected to immunoprecipitation with anti-EGFr antibody and then subjected to Western blot analysis with either anti-EGFr or anti-erbB2 antibody. As shown in Figure 5 , erbB2 was co-immunoprecipitated with EGFr from both control and TPA-treated samples. The relative erbB2 protein level that coimmunoprecipitated with EGFr was signi®cantly higher (*1.3-fold) in TPA-treated epidermis compared to control epidermis (student t-test, P50.05), although the magnitude was not as high as that observed in cultured keratinocytes exposed to EGF.
Activation of c-src in cultured mouse keratinocytes exposed to EGF and in TPA-treated mouse epidermis Analysis of the phosphotyrosine level of erbB2 in mouse epidermis following multiple treatments with TPA, PDD, and 4a-PDD. (a) Mice were treated topically with three applications of 0.2 ml acetone (CTR) or 3.4 nmol TPA in acetone (0.2 ml) and sacri®ced 3 h, 6 h, and 24 h after the last treatment. Epidermal lysates were prepared and immunoprecipitated with 1 mg of polyclonal anti-erbB2 antibody and then subjected to Western blot analysis using anti-erbB2 antibody or PY20. (b) Mice were treated topically with three applications of 0.2 ml acetone (CTR), 0.125 nmol, 0.85 nmol, 3.4 nmol TPA, 10 nmol 4a-PDD, or 10 nmol PDD in acetone (0.2 ml), and sacri®ced 6 h after the last treatment. Epidermal lysates were prepared and immunoprecipitated with 1 mg of polyclonal antierbB2 antibody and then subjected to Western blot analysis using anti-erbB2 antibody or PY20 erbB2 and c-src activation in mouse keratinocytes W Xian et al erbB2, we ®rst analysed the activity of c-src kinase after EGF stimulation in cultured mouse keratinocytes. Cells were stimulated with EGF for 1 min and then cell lysates were prepared as described in Materials and methods. Cell lysates (1.5 mg of protein) were immunoprecipitated with anti-v-src antibody and protein G-plus Agarose. Subsequently, half of the immunoprecipitates were subjected to immunocomplex kinase assay using enolase as the substrate. The other half of the c-src immunoprecipitates were subjected to Western blot analysis. As shown in Figure 6 , the tyrosine phosphorylation level of enolase was dramatically increased in the sample from EGF-stimulated cells (Figure 6a , left side, lanes 1 and 2). Since the c-src protein levels were identical in samples from both control and EGF-treated cells when analysed by Western blotting (Figure 6b , left side, lanes 1 and 2), the increase in phosphorylation level of enolase was due to an increase in c-src kinase activity. Since c-src was activated following exposure of cultured mouse keratinocytes to EGF, we further examined if c-src was also activated in TPA-treated mouse epidermis in vivo. For these experiments, mice were treated topically with three applications of acetone or 3.4 nmol TPA and killed 6 h after the last treatment. Epidermal lysates (1.5 mg of protein) were immunoprecipitated with anti-v-src antibody and subjected to immunocomplex kinase assay and Western blot analysis. As shown in Figure 6 , the tyrosine phosphorylation level of enolase was signi®cantly increased in tissue preparations from TPA-treated mice (Figure 6a , right side, lanes 3 and 4). Again, the increase in phosphorylation level of enolase was due to the increase in c-src kinase activity in the tissue preparation from TPA-treated mice, since the levels of c-src protein were identical in samples from both control and TPAtreated mice (Figure 6b , right side, lanes 3 and 4).
Elevated erbB2 phosphorylation and c-src kinase activity in epidermis of TGFa transgenic mice Based on our current data, we hypothesized that the activation of erbB2 in TPA-treated mouse epidermis was due to elevated EGFr ligands, activation of the EGFr, and at least in part, due to erbB2 : EGFr heterodimer formation. In addition, we hypothesized that c-src activation was due to activation of the EGFr, erbB2, or both. To explore these hypotheses and to further establish the relevance to the process of tumor promotion, we used TGFa transgenic mice where expression of human TGFa was targeted to basal keratinocytes in the epidermis with the human K14 promoter (referred to hereafter as K14.TGFa mice). Figure 7a (right side) shows the histologic characteristics of skin from a 11 week old K14.TGFa transgenic mouse. These mice exhibit a dramatic and persistent epidermal hyperplasia and hyperkeratosis, while the skins of non-transgenic littermates (Figure 7a , left side) were normal for mice at this age. Epidermal lysates were prepared from the K14.TGFa transgenic mice and the non-transgenic littermates and subjected to immunoprecipitation with anti-erbB2 antibody followed by Western blot analysis. As shown in Figure  7b , the phosphotyrosine level of erbB2 was higher (*threefold) in samples from K14.TGFa transgenic mice than from the control mice, while the erbB2 protein levels in these samples were similar. Furthermore, the epidermal lysates were also immunoprecipitated with anti-v-src antibody and the immuno- Activation of c-src kinase activity in cultured mouse keratinocytes exposed to EGF and in epidermis from TPA-treated mice. Lanes 1 and 2: cultured mouse keratinocytes were stimulated with EGF for 1 min and then lysed in lysis buer. Cell lysates were immunoprecipitated with 300 ng of anti-v-src antibody. Half of the immunoprecipitates were subjected to Western blot analysis using anti-v-src antibody (b). The other half of the immunoprecipitates were subjected to src kinase assay for 10 min (a) as described in Materials and methods. Lanes 3 and 4: mice were treated topically with three applications of 0.2 ml acetone (CTR) or 3.4 nmol TPA in 0.2 ml acetone and sacri®ced 6 h after the last treatment. Epidermal lysates were immunoprecipitated with anti-v-src antibody and either subjected to src kinase assay for 3 min or subjected to Western blot analysis as described above erbB2 and c-src activation in mouse keratinocytes W Xian et al precipitates were subjected to a src kinase assay as described in Materials and methods. As shown in Figure 7c , the c-src kinase activity was higher (*2.4-fold) in samples from K14.TGFa transgenic mice than from the control mice. The protein levels of c-src from these samples were similar as determined by Western blot analysis (data not shown).
Discussion
The present study has further investigated the role of erbB family members in skin tumor promotion by examining their tyrosine phosphorylation state, heterodimer formation, and c-src tyrosine kinase activity in cultured mouse keratinocytes exposed to EGF and in mouse epidermis exposed to TPA. The major ®ndings of this study are as follows: (i) EGF induced rapid tyrosine phosphorylation of EGFr, erbB2, and several lower molecular weight proteins (M r *135 kD, *125 kD, and *58 kD) in cultured mouse keratinocytes; (ii) EGF stimulation also induced rapid degradation of EGFr and erbB2 in cultured mouse keratinocytes; (iii) the phosphotyrosine content and level of erbB3 protein was relatively unaected by EGF stimulation; (iv) erbB4 was not detectably present in cultured mouse keratinocytes or mouse epidermis in vivo; (v) EGF stimulation of cultured mouse keratinocytes induced an increase in erbB2 : EGFr heterodimer formation; (vi) the phosphotyrosine level of erbB2 was dramatically elevated in mouse epidermis following treatment with TPA which was associated with a modest but statistically signi®cant increase in erbB2 : EGFr heterodimer formation, but not erbB3 : EGFr heterodimer formation; (vii) dose-response experiments with TPA and structure-activity relationships with several phorbol ester analogs showed that the elevated phosphorylation of erbB2 in mouse epidermis followed closely with tumor-promoting activity; (viii) c-src kinase activity was signi®cantly elevated in both EGF-stimulated keratinocytes and TPA-treated epidermis, and (ix) the phosphotyrosine level of erbB2 and c-src kinase activity were elevated in the hyperplastic epidermis of K14.TGFa transgenic mice. Taken together, the current data suggest a possible role for erbB2 and c-src signaling in the tumor promotion stage of multistage carcinogenesis in mouse skin.
Our initial ®nding of elevated phosphotyrosine level of erbB2 in cultured mouse keratinocytes exposed to EGF (Figure 2 ) is consistent with previous ®ndings in a rat ®broblast cell line (Kokai et al., 1988; Stern and Kemps, 1988) and in a human mammary tumor cell line (King et al., 1988) in which EGF-induced tyrosine phosphorylation of erbB2 was observed. Since EGF does not bind to erbB2 , it appears that the tyrosine phosphorylation of erbB2 is mediated by EGF-induced activation of the EGFr. The physical association of erbB2 and EGFr, i.e. erbB2 : EGFr heterodimer formation, has been demonstrated in transfected murine ®broblasts that coexpressed EGFr and neu (Wada et al., 1990) and in human breast cancer cell lines (Goldman et al., 1990) . It has been suggested that the binding of EGF to the EGFr induced heterodimerization and transphosphorylation between EGFr and neu . Our ®nding that EGF stimulated erbB2 : EGFr heterodimer formation in cultured mouse keratinocytes (Figure 3) suggests that the physical association of EGFr and erbB2 in EGF-stimulated keratinocytes was at least partly responsible for the increased tyrosine phosphorylation of erbB2. The detection of erbB2 : EGFr heterodimer formation even in the absence of EGF stimulation was probably due to the presence of EGFr ligand(s) secreted by the cultured keratinocytes when they were in the serum-free medium. Furthermore, the simultaneous degradation of both EGFr and erbB2 after exposure of cultured mouse keratinocytes to EGF was also observed (Figure 2 ). This degradation may also be due to ligand-induced internalization followed by degradation of erbB2 : EGFr heterodimers in clathrin-coated pits (Beguinot et al., 1984) .
The elevated phosphotyrosine level of erbB2 in mouse epidermis following treatment with TPA was Epidermal lysates were prepared from the K14.TGFa transgenic mice and non-transgenic littermates and subjected to immunoprecipitation with anti-v-src antibody. The immunoprecipitates were subjected to a src kinase assay using a Src Kinase Assay Kit as described in Materials and methods. CTR, protein from nontransgenic littermates; Tg, protein from K14.TGFa transgenic mice erbB2 and c-src activation in mouse keratinocytes W Xian et al quite striking (Figure 4a ). The elevated phosphorylation of erbB2 in mouse epidermis correlated closely with the dose-response for TPA promotion in these mice (Figure 4b ). In addition, structure-activity relationships with phorbol ester analogs also showed that the elevated phosphorylation of erbB2 in mouse epidermis followed closely with tumor promoting activity (Figure 4b ). These data provide evidence for a role of activated erbB2 in the process of skin tumor promotion. We also showed a modest but statistically signi®cant increase in erbB2 : EGFr heterodimer formation in TPA-treated epidermis ( Figure 5 ). While these data suggest that the increased tyrosine phosphorylation of erbB2 in TPA-treated epidermis could be due to erbB2 : EGFr heterodimer formation, the increase in heterodimer formation was small relative to the increased phosphorylation of erbB2. Thus, other mechanisms not involving heterodimer formation may also play a role in mediating TPAinduced erbB2 tyrosine phosphorylation. In addition, a substantial level of erbB2 : EGFr heterodimer formation was observed in samples from control mice, similar to that observed in untreated cultures of mouse keratinocytes. While this may re¯ect the existence of a basal level of ligands for the EGFr in normal mouse epidermis, the phosphotyrosine content of erbB2 was considerably lower in control epidermis than in treated epidermis again suggesting that erbB2 may be activated by mechanisms other than, or in addition to, physical association. Further studies analysing dierent subpopulations of epidermal cells may help shed light on this interesting question.
The mechanism for the elevation of erbB2 phosphotyrosine level and erbB2 : EGFr heterodimer formation in mouse epidermis following treatment with TPA is likely due to the elevation of EGFr ligands in tumor promoter-treated epidermis. Overexpression of TGFa, a major ligand for EGFr, was dramatically induced by various tumor promoters in mouse epidermis (Imamoto et al., 1991; Kiguchi et al., 1995) and in skin tumors (Rho et al., 1994) . In addition, recent experiments from our laboratory have demonstrated that other EGFr ligands including both HB-EGF and amphiregulin are also dramatically elevated in mouse epidermis following treatment with diverse tumor promoters including TPA (Kiguchi et al., 1996) . Thus, the elevated levels of EGFr ligands in tumor promoter-treated mouse epidermis leads to activation of the EGFr (Xian et al., 1995) and this in turn leads to increased tyrosine phosphorylation (possibly through erbB2 : EGFr heterodimer formation) of erbB2. In support of this hypothesis, we showed that K14.TGFa transgenic mice overexpressing TGFa in the epidermis exhibited elevated erbB2 tyrosine phosphorylation and c-src kinase activity (Figure 7 ). These results demonstrate that elevated levels of EGFr ligands such as TGFa alone can bring about the same changes in erbB2 and c-src observed in TPA-treated skin and suggest that this is the mechanism for the eects of TPA.
As part of the present study, we also examined the protein and phosphotyrosine levels of erbB3 and erbB4 in cultured mouse keratinocytes. erbB3 was detectably present in cultured mouse keratinocytes and mouse epidermis in vivo while erbB4 protein was not detected under our current experimental conditions. This latter ®nding was consistent with a recent report by Marikovsky et al. (1995) in which no transcript of erbB4 was detectable in cultured mouse keratinocytes. erbB3 was shown to be tyrosine phosphorylated in response to EGF in human A431 cells (Solto et al., 1994) . The existence of erbB3 : EGFr heterodimer formation in response to EGF was also suggested, although no physical evidence for their association has been reported (Earp et al., 1995) . In our study, however, no erbB3 protein was detected in EGFr immunoprecipitates regardless of whether the cultured keratinocytes were exposed to EGF or not (data not shown). The phosphotyrosine level of erbB3 also was not changed in cultured mouse keratinocytes exposed to EGF (Figure 2a) . Together with the ®nding that the protein level of erbB3 also was not dramatically aected by exposure to EGF (Figure 2) , our results suggest that EGF did not induce heterodimer formation between erbB3 and EGFr in cultured mouse keratinocytes. The absence of erbB3 : EGFr heterodimer formation in response to NDF in cultured mouse keratinocytes was also recently reported (Marikovsky et al., 1995) . Furthermore, activation of PI3 kinase, which is a major substrate for erbB3, was not detected in cultured mouse keratinocytes exposed to EGF (Xian and DiGiovanni, unpublished observation) . Therefore, our current data suggest that erbB3 may not interact signi®cantly with the EGFr in cultured mouse keratinocytes following exposure to EGF.
Recently, Muthuswamy et al. (1994) demonstrated that the activity of c-src kinase was elevated in mammary tumors overexpressing c-neu and suggested that the activation of c-src played a role in mammary tumorigenesis. In light of this observation, we examined c-src and found that its activity was signi®cantly elevated in cultured mouse keratinocytes exposed to EGF and in mouse epidermis following TPA treatment (Figure 6 ). These data suggested that the activation of c-src tyrosine kinase in TPA-treated mouse epidermis was due to activation of the EGFr, erbB2, or both. Since c-src is downstream of many dierent growth factor receptors, like the PDGF receptor and CSF-1 receptor (Gould and Hunter, 1988) , we cannot rule out the possibility that alterations in the activity of these receptors may also contribute to the activation of c-src in TPA-treated mouse epidermis. However, as shown in Figure 7 , activation of EGFr and/or erbB2 appears sucient to activate c-src in epidermis of K14.TGFa transgenic mice. The exact mechanism for c-src activation in TPA-treated epidermis or in the epidermis of K14.TGFa transgenic mice requires further investigation. Muthuswamy et al. (1994) suggested that c-src could be activated by direct interaction with Neu. In fact, the direct interaction of c-src with Neu was later demonstrated in a cell line derived from an activated Neu-induced mouse mammary tumor (Muthuswamy and Muller, 1995) . The interaction of c-src with Neu was shown to be very speci®c, since the SH2 domain of c-src bound to the activated Neu but not the EGFr (Muthuswamy and Muller, 1995) . However, in preliminary experiments we have been unable to detect any association of c-src with the activated erbB2 in cultured mouse keratinocytes or in TPAerbB2 and c-src activation in mouse keratinocytes W Xian et al treated mouse epidermis. Therefore, the exact mechanism for the activation of c-src in our experiments will require further study.
In conclusion, the present study has demonstrated for the ®rst time that both the erbB2 and c-src become activated in cultured mouse keratinocytes exposed to EGF and in mouse epidermis following treatment with TPA. In addition, we have provided data to support the conclusion that both of these changes are involved in the tumor promotion stage of multistage carcinogenesis in mouse skin. The role of erbB2 and c-src in mouse skin carcinogenesis will now be further investigated using transgenic models where erbB2 and c-src are overexpressed in mouse epidermis. In preliminary experiments (D Bol, J Jorcano, and JD DiGiovanni, unpublished observations), expression of the neu oncogene has been targeted to mouse epidermis using the bovine K5 promoter. Founders obtained have a dramatic skin phenotype characterized by elevated interfollicular and follicular proliferation with the latter being quite striking and encompassing most of the dermis. These mice will provide important insight into the role of erbB2 signaling in both normal and abnormal skin processes.
Materials and methods
Reagents
TPA, 4a-PDD, and PDD were obtained from LC Services (Woburn, WA). Anti-phosphotyrosine antibody (PY20) and anti-EGF receptor monoclonal antibody were purchased from Transduction Laboratories (Lexington, KY). Anti-v-src antibody, protein A-agarose and protein G plusagarose were from Oncogene Science, Inc (Cambridge, MA). Anti-EGFr polyclonal antibody, anti-erbB2 polyclonal antibody, and anti-erbB3 polyclonal antibody were from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). EGF and Src Kinase Assay Kit were obtained from Upstate Biotechnology (Lake Placid, NY) and enolase was from Sigma Chemical Co (St Louis, MO). [g-32 P]ATP was from NEN Research Products (Boston, MA).
Animals and treatments
Female SENCAR mice were obtained from the National Cancer Institute (Frederick, MD) and used when 7 ± 9 weeks of age. Prior to treatment, mice were shaved on the dorsal side with surgical clippers. Mice were allowed to rest for 2 days prior to use. TPA (3.4 nmol) was topically applied to the shaved dorsal skin in 0.2 ml acetone. Mice received three treatments according to regimens (twice a week) that yield maximal responses for both epidermal hyperplasia and skin tumor promotion (DiGiovanni, 1992) . The generation of the K14.TGFa mice will be reported elsewhere (Rosenberg and Kucera, manuscript in preparation). K14.TGFa mice used in the current experiments were 8 ± 11 weeks of age.
In vivo sample preparation Whole cell lysates After tropical treatments, SENCAR mice were killed by cervical dislocation. The dorsal skins were treated with a depilatory agent (41 min) followed by washing. The skin was excised and epidermal tissue was scraped o with a razor blade into lysis buer (1% Triton X-100, 10% Glycerol, 50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EGTA, 1.5 mg MgCl 2 , 1 mM PMSF, 20 mg/ml leupeptin, 20 mg/ml aprotinin, 2 mM Na 3 VO 4 , 100 mM NaF, 10 mM r-nitrophenyl phosphate, 5 mg/ml Na-ptosyl-L-lysine chloromethyl ketone (TLCK), and 10 mg/ml tosylsulfonyl phenylalanyl choromethyl ketone (TPCK)) and homogenized with a polytron PT10 homogenizer (3610 s bursts at setting 6). The homogenate was centrifuged at 12 000 g for 15 min at 48C and the supernatant was used immediately for immunoprecipitation.
Microsomal membranes Treated or control dorsal mouse skins were excised and frozen in liquid nitrogen. The frozen skin pieces were ground with a mortar and pestle and homogenized in homogenization buer (200 mM sucrose, 25 mM HEPES, pH 7.4, 5 mM EGTA, 1 mM PMSF, 20 mg/ ml leupeptin, 20 mg/ml aprotinin, 1 mM Na 3 VO 4 , 50 mM NaF, 10 mM sodium pyrophosphate, 10 mM r-nitrophenyl phosphate and 50 mM sodium molybdate). The homogenate was centrifuged at 10 000 g for 30 min at 48C. The supernatant was further centrifuged at 100 000 g for 60 min at 48C. The microsomal fraction (i.e. pellet) was solubilized in lysis buer for 30 min at 48C and centrifuged at 12 000 g for 1 min at 48C. The supernatant was used immediately for immunoprecipitation.
Cell culture and EGF stimulation
Epidermal basal cells from SENCAR mice were isolated and cultured in MEM-2 medium with 1% FBS, 0.04% penicillin-streptomycin solution, and a Ca 2+ concentration of 0.04 mM as previously described (Sawyer et al., 1988) . Cells were plated at a density of 10 7 cells per 100-mm tissue culture dish. Cells were starved for 24 h in 1% BSA/MEM-2 in the absence of all growth factors at day 3. After two washes with the starvation medium, cells were stimulated with 40 ng/ml EGF for 0.5 ± 30 min and lysed with ice cold lysis buer (1% Triton X-100, 10% Glycerol, 50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 1 mM PMSF, 20 mg/ml leupeptin, 20 mg/ml aprotinin, 1 mM Na 3 VO 4 , 50 mM NaF, 10 mM sodium pyrophosphate, 10 mM r-nitrophenyl phosphate and 50 mM sodium molybdate). For immunoprecipitation of c-src, cells were lysed in the same lysis buer used for in vivo sample preparation. Cell lysates were further homogenized with a Polytron homogenizer and centrifuged at 12 000 g for 15 min at 48C. One hundred ml of the lysate was denatured in 26 SDS sample buer and stored at 7708C. The rest of the supernatant was aliquoted and stored at 7708C or used immediately for immunoprecipitation.
Immunoprecipitation
Mouse epidermal lysates or cell culture lysates were incubated with 1 ± 5 mg polyclonal anti-erbB antibodies or 300 ng monoclonal anti-v-src antibody for 1 ± 3 h at 48C and then incubated with protein A-agarose or protein G plus-agarose. The immunocomplex was precipitated by brief centrifugation and washed three times with lysis buer. Immunoprecipitates were subjected to immunocomplex kinase assay prior to SDS ± PAGE. In some experiments, the immunoprecipitates were subjected to SDS ± PAGE directly.
In vitro Src kinase assay
Mouse epidermal lysates or primary keratinocyte lysates were immunoprecipitated with 300 ng of anti-src antibody (Ab.1; Oncogene Science) for 1 h at 48C followed by incubation with protein G-plus Agarose (Oncogene Science) for 1 h at 48C. The precipitates were washed three times with lysis buer, once with 26 kinase buer (200 mM HEPES, pH 7.0, 10 mM MnCl 2 ) and resuspended in 9 ml of 26 kinase buer. The reaction was initiated by addition of 10 mCi of [g-32 P]ATP (6000 Ci/mmol, NEN) and 10 mg of acid-denatured enolase (Sigma). After reacting for 3 ± 10 min at room temperature with agitation, the reaction was stopped by addition of 26 SDS sample buer followed by electrophoresis on 10% SDS/ polyacrylamide gels. The gels were incubated in 1 M KOH for 30 min at 458C, dried, and subjected to autoradiography at 7708C. Alternatively, for studies with TGFa transgenic mice, the c-src kinase activity was measured using a Src Kinase Assay Kit (Upstate Biotechnology) which utilizes a synthetic peptide (KVEKIGEGTYGV-VYK) as the substrate. Mouse epidermal lysates (1.5 ± 3 mg of total protein) were immunoprecipitated with the anti-vsrc antibody and protein G-plus Agarose. The precipitates were washed three times with lysis buer and three times with PBS, and subjected to the kinase assay according to the manufacturer's procedures.
Western blot analysis
After immunoprecipitation and in some cases after subsequent kinase assay, the immunoprecipitates were electrophoresed in 7 ± 10% SDS/polyacrylamide gels according to the method of Laemmli (1970) . In all cases, electrophoresis was performed under reducing conditions. Separated proteins were electrophoretically transferred onto nitrocellulose membranes. After blocking with 1% nonfat powdered milk in TBS (0.5 M NaCl, 20 mM Tris, pH 7.5), the receptor protein level or c-src protein level was detected by incubating the membrane with corresponding antibodies (1 : 100 for anti-erbB antibodies and 1 : 1000 for anti-v-src antibody) and visualized by ECL (Amersham). The phosphotyrosine level of the erbB family proteins was detected using anti-phosphotyrosine antibody (PY20) and again visualized by ECL. Quantitation of the relative dierences between control and treated samples was determined by densitometry using a Visage 60 analyzer (BioImage, Millipore Corporation).
